Home / Technology / CES: Korean Startup Revolutionizes Brain Therapy
CES: Korean Startup Revolutionizes Brain Therapy
9 Jan
Summary
- Phin Stim uses flexible electrodes to gently treat brain conditions.
- The device helps correct irregular brain signals for conditions like epilepsy.
- Gbrain focuses on practical medical applications, not futuristic claims.
Korean neurotechnology startup Gbrain is presenting its Phin Stim system at CES 2026, offering advanced medical solutions for brain disorders. This innovative device targets neurological conditions by delivering precise electrical stimulation to correct irregular brain signals. The technology utilizes ultrathin, flexible electrodes that conform to the brain's surface, enhancing signal quality and minimizing irritation, a significant advancement over rigid implants.
Gbrain's Phin Stim is designed to help patients with conditions such as epilepsy and Parkinson's disease. The system monitors brain activity and intervenes to guide neural pathways back to healthier patterns. While a fully implantable system is the long-term goal, current versions are undergoing clinical trials and regulatory review in Korea, with a prototype recognized as a CES 2025 Innovation Awards Honoree and an updated version for CES 2026.
The company emphasizes practical medical applications over speculative claims, focusing on improving patients' daily lives rather than pursuing enhancement or mind-reading technologies. Gbrain's measured approach highlights manufacturing standards, clinical validation, and regulatory pathways, signaling a commitment to transforming technology into tangible treatments for those in need.
